Clinical Trial Update: GSK1120212 Food-effect Study [Phase 1]

View source ↗

Summary

Phase 1 food-effect study of GSK1120212 (trametinib) in cancer has been completed. The study evaluated whether food intake affects the drug's pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• GSK1120212 (trametinib) (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED